Biopharma Giant Tabs Thought Leader Select for Initiatives in Companion Diagnostics for Oncology Products

July 9, 2013 · Leave a comment

July 9, 2013 (CHAPEL HILL, NC) A global biopharmaceutical leader has chosen Thought Leader Select to perform critical research and advisory work in support of key opinion leader initiatives advancing companion diagnostics for oncology medications.

Thought Leader Select, headquartered in Chapel Hill, North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies, as they reach out to and collaborate with leading medical experts to advance treatment options and promote better health worldwide.

For the engagement, Thought Leader Select’s in-house research team will identify and profile dozens of leading Canadian medical experts in pathology, with a focus on KOLs who have experience in developing companion diagnostics for cancer treatments. The company will also assess the top Canadian medical centers of excellence in pathology, delivering engagement plans that will drive interactions among the biopharma client company and its partners in medicine.

The client company, as it develops companion diagnostics for cancer medications, seeks understanding of the provincial reimbursement process and market access climate for such products, as well as learning the degrees to which medical centers of excellence optimize cancer treatment through the use of companion diagnostics.

Thought Leader Select’s work will combine the company’s objective, validated assessment methodology applied to the skills and experience of key opinion leaders in medicine with a series ... read more »

TAGS:                                                                           

US Biopharma Retains Thought Leader Select for GI Initiatives with KOLs, Centers of Excellence

June 13, 2013 · Leave a comment

June 13, 2013 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in gastroenterology with a leading U.S. biopharmaceutical company.

The company, a global leader in drug development for products aiding patients in recovery from a variety of gastrointestinal surgeries, approached Thought Leader Select for support with planned initiatives with key opinion leaders and centers of excellence in the field.

Thought Leader Select is identifying and profiling thought leaders in colorectal and general surgery across the United States.  The in-house research group at Thought Leader Select is applying its objective, validated methodology to assess the skills and experiences, as well as the clinical and research interests, of KOLs specializing in surgery of the colon, rectum, and bowels.

Known for the versatility of applications for its in-house research, Thought Leader Select’s advisory team will also plan engagement strategies to optimize the talents and contributions that the key opinion leaders will bring to several initiatives for the client company, including late-stage clinical trial work, as well as publication and speaking opportunities. The KOLs will also work on issues within appropriate regulatory bodies, as well as patient advocacy and awareness, and treatment guidelines involvement.

In addition to its work with key opinion leaders, Thought Leader Select’s research group ... read more »

TAGS:                                                     

Canadian Pharma Chooses Thought Leader Select for COPD Key Opinion Leader Engagement Strategy

December 20, 2012 · Leave a comment

December 20, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in pulmonology with a top Canadian biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating chronic obstructive pulmonary disorder (COPD), approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces.  Having already worked with Thought Leader Select to form rosters of key opinion leaders in Canadian rheumatology and oncology circles, the company will formulate its panel of key experts in pulmonology by deploying Thought Leader Select’s team to assess the skills and experiences of physician specialists across the country.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of these leading experts in multiple areas where they collaborate to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.  Among these ... read more »

TAGS:                                                           

International Pharma Chooses Thought Leader Select for Women’s Health Initiative with Key Opinion Leaders, Centers of Excellence

November 6, 2012 · Leave a comment

November 6, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in Canada focused on key opinion leaders and medical centers of excellence in women’s health with an international biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products aimed at improving the health of women, approached Thought Leader Select for support in a variety of collaborative efforts with leading physicians and other health care professionals at leading universities, medical schools, teaching hospitals, and specialty clinics.  The key opinion leaders represent medical experts within the Canadian obstetrics and gynecology community, with areas of sub-specialty including fertility and the treatment of uterine tumors.

Known for the versatility of applications for its in-house research and analysis, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians and other health care professionals, including registered nurses, physician assistants, nurse practitioners, clinical pharmacists, and medical researchers, to advance the science of medicine and patient care in women’s health, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening collaborative ... read more »

TAGS:                                                               

Top US Pharma Chooses Thought Leader Select for Obesity KOL Initiative

October 4, 2012 · Leave a comment

(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in obesity with a top U. S. biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating the condition of obesity, approached Thought Leader Select for support with scientific advisory boards, consulting, and medical science liaison outreach to leading physicians in this area.  Having already worked with Thought Leader Select to form rosters of key opinion leaders in endocrinology, primary care, nursing, pharmacy, and long-term care in the treatment of type I and type II diabetes, the company has now chosen Thought Leader Select to pinpoint the leading experts in the treatment of obesity in the United States.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the area of obesity, and a suite of tools to promote collaborative work ... read more »

TAGS:                                             

Top Canadian Pharma Chooses Thought Leader Select for Diabetes KOLs in Nursing, Pharmacy

September 27, 2012 · Leave a comment

(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top Canadian biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating type and type II diabetes, approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces.  Having already worked with Thought Leader Select to form a roster of key opinion leaders in Canadian endocrinology circles, the company will round out its roster of key opinion leaders by deploying Thought Leader Select’s team to assess the skills and experiences of registered nurses and clinical pharmacists around the country.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of registered nurses and pharmacists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.

“Thought ... read more »

TAGS:                                                 

Global Pharmaceutical Company Tabs Thought Leader Select for Gastroenterology Key Opinion Leader Partnership

June 21, 2012 · Leave a comment

June 21, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top 10 global biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating exocrine pancreatic insufficiency (EPI), approached Thought Leader Select for support with scientific advisory boards in support of a new product initiative.  To meet the strategic needs of the company’s advisory board activities in support of the new treatment, Thought Leader Select will deploy its in-house research group for an assessment of community-based key opinion leaders in gastroenterology throughout the United States.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in multiple areas where they advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

For the national assessment, the Thought Leader Select research group will collaborate with a team of national key opinion leaders in gastroenterology to identify community-based physicians for grassroots-level scientific advisory work. Thought Leader Select will combine the key opinion leader recommendations with the experience data to optimize a pool of leading physicians with broad representation across multiple geographic ... read more »

TAGS:                                             

Understanding the Sunshine Act—Part One

March 27, 2012 · Leave a comment

Industry Insights from Kristen Smithwick

Albeit a bit late, the U. S.  Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on the Patient Protection & Affordable Care Act’s Physician Payments Sunshine Provision (also known as the “Sunshine Act”) to implement it as law.

CMS invited comments on the proposed rule through mid-February 2012, and a recent webcast, sponsored by PharmaLive’s Pharmalot, featured key facts and summaries of comments on the proposed rule. Working for a provider of research and consulting to the biopharmaceutical, medical device, and diagnostics industries on relationships with physicians and other health care providers, I enjoyed the opportunity to join the webcast, led by experts from Buchanan Ingersoll & Rooney, P.C., and am eager to share some of my key takeaways.

As mentioned in previous Thought Leader Select Blog posts, the Sunshine Act, as with many laws and regulations, is full of unintended consequences – some positive and some negative. Lance K. Stell, medical ethics teacher at Davidson College and Carolinas Medical Center, reports in his USA Today op-ed piece that the “Sunshine Act will cost far more than the $224 million estimated for just the first year of compliance” and that “the biggest cost will be the valuable, socially useful physician-industry collaborations that simply won’t occur.” Of course, the idea of ... read more »

TAGS:                                                       

Transparency and the Sunshine Provision – Is This a Good or Bad Thing?

March 17, 2011 · Leave a comment

Industry Insights from Paul Meade, M.Sc., MPH

The Physician Payment Sunshine Provision is a part of the Patient Protection and Affordable Care Act passed by the U. S. Congress in March of last year. The provision will go into effect on January 1, 2012. Many people in the healthcare industry are struggling to determine if this provision is a good thing or a bad one. Truth be told, it is a bit of both—good, in that it ensures complete transparency among health care providers and manufacturers of pharmaceuticals and medical devices, and bad, because it may expose the benefits some healthcare professionals gain from interacting with some manufacturers.

For years, healthcare professionals have been interacting with manufacturers in many ways; when providers offer their professional services, they expect and receive compensation for their time and knowledge, as would experts in any other industry. Every industry has its experts, and healthcare is no exception. There are healthcare experts in a variety of functional areas and in all therapeutic areas. These experts have medical information and knowledge that is valuable to healthcare manufacturers as they develop and commercialize their products and services. Acting as consultants to industry manufacturers, experts offer guidance in the development of new products, from determining unmet medical needs to suggestions on how to price new products.

Is it fair to compensate ... read more »

TAGS:                                       

How Will Healthcare Reform Impact Your Next Investigator or Advisory Board Meeting?

February 28, 2011 · Leave a comment

Regulatory Guidance from Aprel Buonpane

The main components of the new US healthcare reform legislation will continue to be subjects for debate in the coming months and years, but tucked in among all of the changes for Medicare beneficiaries, coverage for pre-existing conditions, and the effects on small business owners lies a provision that most laypeople would not even notice. This provision, however, has the attention of US drug and device manufacturers and cannot be ignored.

The Physician Payment Sunshine Provision, also known as the Sunshine Act, requires that these companies publicly report gifts and payments made to physicians and other entities such as teaching hospitals. The intention of the provision is to address the public’s perception that biopharmaceutical companies use payments to influence a physician’s prescription-writing habits and to improve transparency as to what actually does exchange hands, in the form of services and remuneration for those services, and why. Drug and device manufacturers must begin capturing this data in January 2012 and must make their first report on these activities to the Department of Health and Human Services by March 2013. This provision has far-reaching implications for how the medical meetings and event industry will conduct its business in service of the healthcare community for years to come.

The new law requires that every dollar spent on physicians and health care ... read more »

TAGS:                                               

Older posts »